Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi

Cristina Capodicasa, Marcello Catellani, Ilaria Moscetti, Carla Bromuro, Paola Chiani, Antonella Torosantucci, Eugenio Benvenuto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immunoglobulins A (IgA) are crucially involved in protection of human mucosal surfaces from microbial pathogens. In this work, we devised and expressed in plants recombinant chimeric antifungal antibodies (Abs) of isotype A (IgA1, IgA2, and scFvFcA1), derived from a murine mAb directed to the fungal cell wall polysaccharide β-glucan which had proven able to confer protection against multiple pathogenic fungi. All recombinant IgA (rIgA) were expressed and correctly assembled in dimeric form in plants and evaluated for yield, antigen-binding efficiency and antifungal properties in vitro, in comparison with a chimeric IgG1 version. Production yields and binding efficiency to purified β-glucans showed significant variations not only between Abs of different isotypes but also between the different IgA formats. Moreover, only the dimeric IgA1 was able to strongly bind cells of the fungal pathogen Candida albicans and to restrain its adhesion to human epithelial cells. Our data indicate that IgG to IgA switch and differences in molecular structure among different rIgA formats can impact expression in plant and biological activity of anti-β-glucans Abs and provide new insights for the design of recombinant IgA as anti-infective immunotherapeutics, whose potential is still poorly investigated.

Original languageEnglish
Pages (from-to)2729-2738
Number of pages10
JournalBiotechnology and Bioengineering
Volume114
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Glucans
Fungi
Antibodies
Cell Wall
Immunoglobulin A
Cells
Pathogens
Candida
Antigens
Polysaccharides
Bioactivity
Molecular structure
Adhesion
Switches
Immunoglobulin G
Molecular Structure
Candida albicans
Anti-Idiotypic Antibodies
Epithelial Cells

Keywords

  • anti-infectious IgA
  • antigen binding efficiency
  • fungal infections
  • immunotherapy
  • plant pharming
  • recombinant IgA

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi. / Capodicasa, Cristina; Catellani, Marcello; Moscetti, Ilaria; Bromuro, Carla; Chiani, Paola; Torosantucci, Antonella; Benvenuto, Eugenio.

In: Biotechnology and Bioengineering, Vol. 114, No. 12, 01.12.2017, p. 2729-2738.

Research output: Contribution to journalArticle

Capodicasa, Cristina ; Catellani, Marcello ; Moscetti, Ilaria ; Bromuro, Carla ; Chiani, Paola ; Torosantucci, Antonella ; Benvenuto, Eugenio. / Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi. In: Biotechnology and Bioengineering. 2017 ; Vol. 114, No. 12. pp. 2729-2738.
@article{db935d1bce274c3393168b57c3b7bce9,
title = "Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi",
abstract = "Immunoglobulins A (IgA) are crucially involved in protection of human mucosal surfaces from microbial pathogens. In this work, we devised and expressed in plants recombinant chimeric antifungal antibodies (Abs) of isotype A (IgA1, IgA2, and scFvFcA1), derived from a murine mAb directed to the fungal cell wall polysaccharide β-glucan which had proven able to confer protection against multiple pathogenic fungi. All recombinant IgA (rIgA) were expressed and correctly assembled in dimeric form in plants and evaluated for yield, antigen-binding efficiency and antifungal properties in vitro, in comparison with a chimeric IgG1 version. Production yields and binding efficiency to purified β-glucans showed significant variations not only between Abs of different isotypes but also between the different IgA formats. Moreover, only the dimeric IgA1 was able to strongly bind cells of the fungal pathogen Candida albicans and to restrain its adhesion to human epithelial cells. Our data indicate that IgG to IgA switch and differences in molecular structure among different rIgA formats can impact expression in plant and biological activity of anti-β-glucans Abs and provide new insights for the design of recombinant IgA as anti-infective immunotherapeutics, whose potential is still poorly investigated.",
keywords = "anti-infectious IgA, antigen binding efficiency, fungal infections, immunotherapy, plant pharming, recombinant IgA",
author = "Cristina Capodicasa and Marcello Catellani and Ilaria Moscetti and Carla Bromuro and Paola Chiani and Antonella Torosantucci and Eugenio Benvenuto",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/bit.26403",
language = "English",
volume = "114",
pages = "2729--2738",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "12",

}

TY - JOUR

T1 - Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi

AU - Capodicasa, Cristina

AU - Catellani, Marcello

AU - Moscetti, Ilaria

AU - Bromuro, Carla

AU - Chiani, Paola

AU - Torosantucci, Antonella

AU - Benvenuto, Eugenio

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Immunoglobulins A (IgA) are crucially involved in protection of human mucosal surfaces from microbial pathogens. In this work, we devised and expressed in plants recombinant chimeric antifungal antibodies (Abs) of isotype A (IgA1, IgA2, and scFvFcA1), derived from a murine mAb directed to the fungal cell wall polysaccharide β-glucan which had proven able to confer protection against multiple pathogenic fungi. All recombinant IgA (rIgA) were expressed and correctly assembled in dimeric form in plants and evaluated for yield, antigen-binding efficiency and antifungal properties in vitro, in comparison with a chimeric IgG1 version. Production yields and binding efficiency to purified β-glucans showed significant variations not only between Abs of different isotypes but also between the different IgA formats. Moreover, only the dimeric IgA1 was able to strongly bind cells of the fungal pathogen Candida albicans and to restrain its adhesion to human epithelial cells. Our data indicate that IgG to IgA switch and differences in molecular structure among different rIgA formats can impact expression in plant and biological activity of anti-β-glucans Abs and provide new insights for the design of recombinant IgA as anti-infective immunotherapeutics, whose potential is still poorly investigated.

AB - Immunoglobulins A (IgA) are crucially involved in protection of human mucosal surfaces from microbial pathogens. In this work, we devised and expressed in plants recombinant chimeric antifungal antibodies (Abs) of isotype A (IgA1, IgA2, and scFvFcA1), derived from a murine mAb directed to the fungal cell wall polysaccharide β-glucan which had proven able to confer protection against multiple pathogenic fungi. All recombinant IgA (rIgA) were expressed and correctly assembled in dimeric form in plants and evaluated for yield, antigen-binding efficiency and antifungal properties in vitro, in comparison with a chimeric IgG1 version. Production yields and binding efficiency to purified β-glucans showed significant variations not only between Abs of different isotypes but also between the different IgA formats. Moreover, only the dimeric IgA1 was able to strongly bind cells of the fungal pathogen Candida albicans and to restrain its adhesion to human epithelial cells. Our data indicate that IgG to IgA switch and differences in molecular structure among different rIgA formats can impact expression in plant and biological activity of anti-β-glucans Abs and provide new insights for the design of recombinant IgA as anti-infective immunotherapeutics, whose potential is still poorly investigated.

KW - anti-infectious IgA

KW - antigen binding efficiency

KW - fungal infections

KW - immunotherapy

KW - plant pharming

KW - recombinant IgA

UR - http://www.scopus.com/inward/record.url?scp=85029233306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029233306&partnerID=8YFLogxK

U2 - 10.1002/bit.26403

DO - 10.1002/bit.26403

M3 - Article

C2 - 28832951

AN - SCOPUS:85029233306

VL - 114

SP - 2729

EP - 2738

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 12

ER -